The Global Centre for Risk and Innovation (GCRI)
Synthetic biology applies engineering principles to biology: designing genetic systems, building them, testing how they behave and learning from the results. It promises new medicines, materials, fuels and agricultural products. This topic, studied at Biotechnology and Biosecurity, a platform of The Global Centre for Risk and Innovation (GCRI), examines how the design-build-test-learn cycle is changing, what safeguards accompany it and how governance can keep pace without stifling beneficial research.
GCRI · In development · service level R0
Synthetic biology is the design and construction of new biological parts, devices and systems, or the redesign of existing ones, for useful purposes. This page covers the oversight it needs: institutional review, biosafety containment, screening and governance of research, and the public consultation that responsible innovation asks for. It describes governance and capacity, not laboratory methods.
For synthetic biology, in GCRI's spatial-intelligence reading, the map opens on crop greenness, population density, daytime surface heat and true-colour imagery, framed on West Africa; 2 further NASA layers wait in the list.
The interactive map needs JavaScript; the layer list and sources are below.
Layers 4
Environmental exposure, for this page
Keyboard, with the map focused
Hold Ctrl or ⌘ and scroll to zoom
Latest available
NASA GIBS / EOSDIS · ASTER GDEM (METI, NASA) · Blue Marble (NASA) · © OpenStreetMap contributors (ODbL) · Natural Earth
Loading the latest NASA imagery.
Drag to move. Ctrl or ⌘ and scroll, pinch or the buttons to zoom; hover for the values under the pointer; reset returns to the region.
For synthetic biology, in GCRI's spatial-intelligence reading, the map opens on crop greenness, population density, daytime surface heat and true-colour imagery, framed on West Africa; 2 further NASA layers wait in the list.Satellite and model products as NASA publishes them, each with its own date; indicators, not assessments of any place; claim ceiling INTEGRATED.
Layers and dates
The working screen behind this subject: its structure, terms and states. Names are placeholders and values illustrative.
Synthetic biology · National committee · Review year 2
| Institution A | Active | Q4 | 96 | Current |
| Research campus | Active | Q1 | 63 | Audit due |
| Biomanufacturing site | Forming | none | 54 | Support |
| Diagnostic network | Active | Q2 | 87 | Current |
Synthetic biology rests on reading DNA through sequencing, writing it through synthesis and editing it with precise tools, combined with standardized genetic parts and computational design. Automation in so-called biofoundries and cloud laboratories has accelerated the cycle of design and testing. Costs have fallen and capabilities have spread to universities, start-ups and community laboratories worldwide.
Safeguards operate at several layers: screening of synthetic DNA orders by providers, institutional biosafety review, containment of engineered organisms, and built-in biological controls that limit survival outside the laboratory. Each layer has gaps. Screening practices vary between providers and jurisdictions, and design tools increasingly operate beyond the reach of traditional oversight.
The platform works at the level of governance, evaluation and risk methods. It publishes no protocols, techniques or information that would increase anyone's capacity to cause harm.
Horizon scanning and expert elicitation assess capabilities and maturity, drawing on biotechnology platforms.
Structured frameworks weigh hazard, exposure and consequence, with uncertainty expressed through probability and statistics.
Comparative studies of oversight regimes, screening practices and institutional review.
Technology moves faster than evidence about its risks, expert judgement varies, and information about misuse potential must be handled with care.
Each term as this page uses it. Where a standard-setting body defines the term, the wording follows that body.
| Term | Definition |
|---|---|
| Biosafety | Measures that assess and manage risks to health and the environment from living modified organisms, governed internationally by the Cartagena Protocol. |
| Dual-use research of concern | Life sciences research that could be directly misapplied to threaten health, agriculture, the environment or security. |
| Responsible innovation | Anticipating and governing the effects of new technology together with society. |
| Living modified organism | An organism with a novel combination of genetic material obtained through modern biotechnology, as the Cartagena Protocol defines it. |
This evidence informs research funding conditions, screening policies, institutional review practice and regulatory design. Funders, research institutions, DNA synthesis providers and national regulators decide within their mandates. Governance dialogue is convened by Health and Biosecurity Governance at The Global Risks Forum (GRF). Related topics are biomanufacturing, dual use and ethics and laboratory biosafety and biosecurity; methods sit on biotechnology platforms and molecular and life sciences.
Published analysis on this topic is designed to carry a named subject reviewer, its references and the views of independent specialists, including biosafety professionals and those who disagree.
The current service level is R0: information and enquiries. An enquiry receives a reference and names the next step; applications, payments, compute allocations and registrations open only when their team, terms and review capacity exist.